Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Accounts Payables (2020 - 2025)

Rani Therapeutics Holdings has reported Accounts Payables over the past 6 years, most recently at $309000.0 for Q4 2025.

  • Quarterly results put Accounts Payables at $309000.0 for Q4 2025, down 77.26% from a year ago — trailing twelve months through Dec 2025 was $309000.0 (down 77.26% YoY), and the annual figure for FY2025 was $309000.0, down 77.26%.
  • Accounts Payables for Q4 2025 was $309000.0 at Rani Therapeutics Holdings, down from $2.5 million in the prior quarter.
  • Over the last five years, Accounts Payables for RANI hit a ceiling of $2.5 million in Q3 2025 and a floor of $309000.0 in Q4 2025.
  • Median Accounts Payables over the past 5 years was $1.4 million (2023), compared with a mean of $1.3 million.
  • Peak annual rise in Accounts Payables hit 255.34% in 2025, while the deepest fall reached 77.26% in 2025.
  • Rani Therapeutics Holdings' Accounts Payables stood at $1.1 million in 2021, then surged by 35.19% to $1.5 million in 2022, then crashed by 55.62% to $648000.0 in 2023, then skyrocketed by 109.72% to $1.4 million in 2024, then plummeted by 77.26% to $309000.0 in 2025.
  • The last three reported values for Accounts Payables were $309000.0 (Q4 2025), $2.5 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.